3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
27
Prostatic Neoplasms
22
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Neoplasms
10
Lung Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Interventions
Paclitaxel
4
pembrolizumab
3
Cisplatin
3
Doxorubicin
2
Carboplatin
2
Brachytherapy
2
Biopsy
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
relugolix
1
dostarlimab
1
dehydroftorafur
1
belzutifan
1
Watchful Waiting
1
Vaginal Smears
1
VMBP protocol
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Taxes
1
Sutures
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Pregnancy Tests
1
Practice Guidelines as Topic
1
Platinum
1
Papanicolaou Test
1
Oxaliplatin
1
Mitozytrex
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Neoplasms
×
Docetaxel
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled